ENLV supply chain intelligence for Enlivex Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Enlivex Ltd. (ENLV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SNYNF | Sanofi | 72% | g other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of an approval, or suspension of production. As a result, our business, financial condi… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ENLV graph: g other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of a… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLGN | CollPlant Biotechnologies Ltd. | 72% | fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial … |
| CLGN | CollPlant Biotechnologies Ltd. | 72% | Reciprocal relationship from CLGN graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from ENLV graph: fair value of share-based payment a… |
| INDP | Indaptus Therapeutics, Inc. | 72% | Reciprocal relationship from INDP graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent un… |
| INDP | Indaptus Therapeutics, Inc. | 72% | fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent unc… |
| JNJ | Johnson & Johnson | 72% | fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial … |
| MCRB | Seres Therapeutics, Inc. | 72% | fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial … |
| MCRB | Seres Therapeutics, Inc. | 72% | Reciprocal relationship from MCRB graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent un… |
| MRK | Merck & Co., Inc. | 72% | fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial … |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent unc… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including re… |
| SECURITIES-INVESTOR-PROTECTION-CORPORATION | SECURITIES-INVESTOR-PROTECTION-CORPORATION | 62% | ularly in foreign countries in which laws may not protect our proprietary rights as fully as in the United States and other developed economies. Moreover, if we lose any key personnel, we may not be … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ENLV-DEBT-9307 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2013-12-31. |
| ENLV-DEBT | Debt stack $32.6M | 90% | Market cache reports total debt of $32.6M. |
| ENLV-DEBT-9306 | Warrants outstanding: 1 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ENLV-OWNER-XTX-TOPCO-LTD | Xtx Topco Ltd | 95% | 13F/ownership overlay lists Xtx Topco Ltd; shares held 61,800; ownership 0.33%; value $64,889; as of 2025-12-31. |
| ENLV-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 85,098; ownership 0.46%; value $89,352; as of 2025-12-31. |
| ENLV-OWNER-TWO-SIGMA-INVESTMENTS-LP | Two Sigma Investments, LP | 95% | 13F/ownership overlay lists Two Sigma Investments, LP; shares held 195,126; ownership 1.05%; value $204,882; as of 2025-12-31. |
| ENLV-OWNER-VIRTU-FINANCIAL-LLC | Virtu Financial LLC | 95% | 13F/ownership overlay lists Virtu Financial LLC; shares held 47,381; ownership 0.26%; value $49,750; as of 2025-12-31. |
| ENLV-OWNER-JANE-STREET-GROUP-LLC | Jane Street Group, LLC | 95% | 13F/ownership overlay lists Jane Street Group, LLC; shares held 74,082; ownership 0.40%; value $77,786; as of 2025-12-31. |
| ENLV-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 34,988; ownership 0.19%; value $36,737; as of 2025-12-31. |
| ENLV-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 200,627; ownership 1.08%; value $210,658; as of 2025-12-31. |
| ENLV-OWNER-RENAISSANCE-TECHNOLOGIES-LLC | Renaissance Technologies, LLC | 95% | 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 313,628; ownership 1.69%; value $329,309; as of 2025-12-31. |
| ENLV-OWNER-HRT-FINANCIAL-LP | HRT Financial LP | 95% | 13F/ownership overlay lists HRT Financial LP; shares held 153,990; ownership 0.83%; value $161,689; as of 2025-12-31. |
| ENLV-OWNER-INVESCO-LTD | Invesco Ltd. | 95% | 13F/ownership overlay lists Invesco Ltd.; shares held 60,920; ownership 0.33%; value $63,965; as of 2025-12-31. |
| ENLV-OWNER-DIAMETRIC-CAPITAL-LP | Diametric Capital, LP | 90% | 13F overlay lists Diametric Capital, LP as top holder; 36 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALC | Alcon Inc. | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 1 | ['customer'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| ESTA | Establishment Labs Holdings Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ADAG | Adagene Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 |